Podcasts about mesenchymal stem cells

Mesenchymal Stem Cells, the future of cartilage therapy, is here today, which means that with just one gel injection, you could completely rejuvenate your knee.More information is available at https://londoncartilage.com/stem-cell-cartilage-therapy/ London Cartilage Clinic City: London Address: 108 Harley Street London, W1G 7ET United Kingdom Website: https://londoncartilage.com/ Phone: +44 330 043 2571 Email: team@londoncartilage.com

Subscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsStem cell therapy is transforming regenerative medicine, offering powerful treatments for chronic inflammation, aging, autism, and more. In this eye-opening interview, triple board-certified physician Dr. Joy Kong reveals how stem cells work, why they're more than just anti-aging tools, and how DNA and energy-based healing could be the future of healthcare.You'll learn how IV stem cell therapy works, how to avoid dangerous clinics, and why stem cells are revolutionizing treatment for autoimmune conditions, mental health, and skin and hair rejuvenation. Dr. Kong also shares her journey from psychiatry to founding the American Academy of Integrative Cell Therapy.This episode covers the powerful regenerative potential of stem cells, the rise of IV therapy, how to avoid unregulated clinics, and why true healing must always be holistic. Whether you're seeking answers for chronic illness or curious about the future of longevity, this is a must-watch.Connect further to Hol+ at https://holplus.co/- Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+.About Dr. Joy Kong:Dr. Joy Kong is a triple board-certified anti-aging physician and stem cell specialist, renowned for her expertise in stem cell therapy and commitment to educating both physicians and the public. With a strong presence in the industry, she has established herself as a trusted voice through her extensive lecturing at national and international conferences, as well as her publications in scientific journals.As a dedicated educator and pioneer in the field of regenerative medicine, Dr. Kong has founded the American Academy of Integrative Cell Therapy (AAICT) and trained numerous physicians from around the world. Her innovative approach has also led to the creation of Chara Health USA and Chara Biologics, premier companies providing cutting-edge products and services to patients across the United States. With numerous accolades, including Stem Cell Doctor of the Year and Stem Cell Doctor of the Decade, Dr. Kong continues to be a respected figure in the medical community, dedicated to advancing the field of regenerative medicine and improving patient outcomes through her emphasis on scientific data, passion, authenticity, and integrity.Her inspiring memoir, "Tiger of Beijing," which recounts her remarkable journey as an immigrant from China at the age of 20 starting with her visa rejection in 1991, was named 2020 Book of the Year by IAOTP.Stay ConnectedSubscribe to the audio podcast: https://holplus.transistor.fm/subscribeSubscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsFollow Dr. Taz on Instagram: https://www.instagram.com/drtazmd/https://www.instagram.com/liveholplus/Join the conversation on X: https://x.com/@drtazmdTikTok: https://www.tiktok.com/@drtazmdFacebook: https://www.facebook.com/drtazmd/Follow Dr. Kong on Instagram:https://www.instagram.com/dr_joy_kong/Host & Production TeamHost: Dr. Taz; Produced by Rainbow Creative (Executive Producer: Matthew Jones; Lead Producer: Lauren Feighan; Editors: Jeremiah Schultz and Patrick Edwards)Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+01:58 - Dr. Joy Kong's Journey into Regenerative Medicine  03:30 - Stem Cell Therapy for Autism and Chronic Conditions  05:15 - Inside the American Academy of Integrative Cell Therapy  08:14 - Stem Cells as Energy and DNA-Based Healing  12:31 - How Stem Cells Navigate the Body and Target Inflammation  16:36 - Umbilical vs. Fat-Derived Stem Cells: Safety and Sourcing  20:53 - Avoiding Stem Cell Scams: Testing, Regulations, and Red Flags  26:53 - IV Stem Cell Therapy: Benefits, Applications, and Costs  43:24 - Stem Cells for Skin, Hair Loss, and Anti-Aging Results

Send us a textDr. Kilian Kelly, Ph.D. is Chief Executive Officer and Managing Director of Cynata Therapeutics ( https://cynata.com/ ), a stem cell and regenerative medicine company that is known for its proprietary Cymerus platform, for the scalable and consistent production of mesenchymal stem cell (MSC)-based therapies.Unlike traditional MSC therapies that rely on multiple donors, the Cymerus manufacturing process ensures that cells for therapeutic use can be produced in virtually limitless quantities from a single donor – making the opportunities endless and attractive from a manufacturing standpoint. The company has completed Phase I studies for Graft vs Host disease & Diabetic Foot Ulcers and have a number of Phase II, and even have a Phase III clinical trial, in progress.Dr. Kelly has over 20 years' experience in biopharmaceutical research and development, including almost 15 years focused on the development of mesenchymal stem cell (MSC) based therapies. He joined Cynata in March 2014, initially as Vice President, Product Development, then Chief Operating Officer from May 2019, and since July 2023 has been CEO & MD. At Cynata, he has overseen all stages of the development of the Cymerus induced pluripotent stem cell (iPSC)-derived MSC technology, including the first completed clinical trial of any iPSC-derived product worldwide.Dr. Kelly previously held positions at Biota Pharmaceuticals, Mesoblast Limited, Kendle International, Amgen and AstraZeneca. Dr. Kelly holds a Masters in Pharmacy degree from the Robert Gordon University, Aberdeen, a Ph.D. in Pharmaceutical Sciences from Strathclyde University, Glasgow, and he is a Graduate of the Australian Institute of Company Directors (AICD), Melbourne. He is a member of the International Society for Cell and Gene Therapy (ISCT), the International Society for Stem Cell Research (ISSCR), the Royal Pharmaceutical Society and the AICD.Dr. Kelly also serves on the ISCT Asia-Pacific Industry Committee, the ISSCR Best Practices Working Group for the Development of PSC-Derived Therapies and the Industry Interface Committee of the Center for Commercialization of Regenerative Medicine (CCRM) Australia.#KilianKelly #CynataTherapeutics #InducedPluripotentStemCells #MesenchymalStemCells #Immunomodulation #Immunoregulation #Mesenchymoangioblasts #GraftVersusHostDisease #GVHD #MSC #iPSC #IschaemicHeartDisease #Osteoarthritis #AcuteRespiratoryDistressSyndrome #ARDS #Inflammation #Secretome #Paracrine #RegenerativeMedicine #DiabeticWounds #KidneyTransplantation #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

More good news about Omega-3s for heart health; Addressing early-stage dementia; When Lyme Disease doesn't respond to antibiotics; Ultra-processed food hijacks brain within days; Exosomes and adaptive deep-brain stimulation offer hope for Parkinson's; Psychologists conclude relentless “pursuit of happiness” may exhaust our brains' control centers; A common over-the-counter drug taken in pregnancy may hike offsprings' risk of ADHD. 

Send us a textKevin Caldwell is CEO, Co-Founder & President of Ossium Health ( https://ossiumhealth.com/ ), a commercial stage bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects.  Mr. Caldwell built Ossium from a small startup into the clinical stage bioengineering company it is today, setting the company's mission to improve human health through bioengineering and designed its platform-based model for cellular therapeutics development. He has led the company's successful pursuit, negotiation, and execution of more than 50 business relationships, including 5 successful fundraisings and dozens of supply partnerships, clinical partnerships, and commercial contracts with biopharmaceutical companies. After seven years of strategic engagement and networking, Mr. Caldwell drove the team to successfully secure a transformative federal contract with BARDA (Biomedical Advanced Research and Development Authority) that validates Ossium's innovative approach. This milestone represents the culmination of persistent relationship-building, targeted proposals, and  unwavering commitment to addressing national biomedical challenges through cutting-edge technology and collaborative partnerships.Prior to founding Ossium, Mr. Caldwell served as an Engagement Manager at McKinsey's San Francisco office where he advised clients in the biotechnology and healthcare sectors. His projects ranged from due diligence of acquisition targets in the biotech startup ecosystem to restructuring distressed biopharma companies. Mr. Caldwell led more than 20 engagements with more than a dozen clients, leading teams that advised clients on revenue growth, go to market strategy, and organizational restructuring.Before McKinsey, Mr. Caldwell served as a Senior Investment Associate at Bridgewater Associates where he did quantitative research for the firm's global macro investments. Mr. Caldwell studied Physics and Economics at MIT before receiving his JD from Harvard Law School. In addition, he is a member of the Young Presidents Organization (YPO), and a Fellow of the Leaders in Tech Program.#KevinCaldwell #OssiumHealth #BoneMarrow #HematopoieticStemCellTransplantation #HSCT #MesenchymalStemCells #Leukemia #Lymphoma #Myeloma #SickleCellDisease #OrganTransplantRejection #GraftVersusHostDisease #GVHD #BARDA #ASPR #CBRN #NuclearEmergencyPreparedness #Longevity #Aging #Frailty #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

BUFFALO, NY- January 14, 2025 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 22 on November 26, 2024, entitled “When do the pathological signs become evident? Study of human mesenchymal stem cells in MDPL syndrome.” Researchers from the University of Rome Tor Vergata, Fondazione Policlinico Tor Vergata, Roma Tre University, and Meyer Children's Hospital IRCCS have identified early cellular changes associated with Mandibular Hypoplasia, Deafness, Progeroid Features, and Lipodystrophy (MDPL) syndrome, a rare genetic aging disorder caused by a mutation in the POLD1 gene. MDPL leads to fat loss, distinct facial features, and metabolic disturbances. This study aimed to better understand how MDPL progresses at the cellular level. MDPL syndrome is extremely rare, with only a few documented cases worldwide, making it difficult to study. To investigate the disease, researchers Spitalieri Paola, Guerrieri Lara, Murdocca Michela, Di Cesare Silvia, Maccaroni Serena, Pecorari Rosalba, Nardone Anna Maria, Candi Eleonora, Colasuonno Fiorella, Gori Giulia, Traficante Giovanna, Novelli Giuseppe, and Sangiuolo Federica, converted skin cells from three female MDPL patients and two healthy donors into human induced pluripotent stem cells (hiPSCs). These hiPSCs were then transformed into mesenchymal stem cells (MSCs), cells that can form tissues like bone and fat, which are primarily affected in MDPL syndrome. The study revealed that MSCs from MDPL patients exhibited signs of premature aging much earlier than expected. The cells had irregular shapes, grew at a slower rate, and showed higher levels of cellular stress. “These cells differentiate with lower efficiency, proliferate more slowly and have abnormal mitochondrial activity with increased production of ROS. Furthermore, the telomeres show evident shortening.” All the findings suggest that aging-related changes may occur long before patients display visible symptoms of the disease. This highlights the need for early diagnosis and intervention, which could delay or even prevent the most debilitating effects of MDPL syndrome. In summary, this study offers new perspectives on the initial cellular impacts of MDPL, opening the door for the creation of novel treatments. The findings highlight the potential for personalized therapies and emphasize the critical role of lab-created hiPSCs in advancing research on rare genetic diseases and age-related conditions. DOI - https://doi.org/10.18632/aging.206159 Corresponding author - Sangiuolo Federica - sangiuolo@med.uniroma2.it Video short - https://www.youtube.com/watch?v=DLXD2ztPTm0 Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206159 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, MDPL syndrome, MSCs, hiPSCs, POLD1 gene About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY - December 3, 2024 – A new #review was #published in Oncotarget's Volume 15 on November 22, 2024, entitled “Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists." Authored by Theia Minev, Shani Balbuena, Jaya Mini Gill, Francesco M. Marincola, Santosh Kesari, and Feng Lin from CureScience Institute, Sonata Therapeutics, and Pacific Neuroscience Institute and Providence Saint John's Health Center, this review explores the potential role of mesenchymal stem cells (MSCs) in cancer treatment. These stem cells can naturally target tumors and deliver therapeutic agents directly to cancer cells, potentially improving treatment outcomes while reducing side effects commonly associated with traditional therapies like chemotherapy. However, the authors also note significant challenges, pointing out that under certain conditions, MSCs may unintentionally promote tumor growth, highlighting the need for careful therapeutic design. MSCs are cells that can develop in different types of tissues, such as bone, fat, or cartilage, and act as natural repair agents. What makes them particularly special is their ability to respond to biological signals, like inflammation, which is often present in cancer. This enables them to locate tumors, and once there, they can deliver cancer treatments directly to the affected area. Clinical trials are already investigating MSC-based treatments for cancers such as brain tumors, melanoma, and ovarian cancer. Some results are promising, showing that MSCs can effectively deliver treatments and boost the immune system's fight against cancer. However, other trials have also revealed the complexities of MSC behavior, including variability in their effects and the potential to create conditions that support tumor growth. “This variability may be due to the tumor immune microenvironment's effects, where immune cells are inhibited by various factors, creating a conducive environment for tumor growth.” The authors also suggest that “Developing personalized MSC therapies tailored to the specific characteristics of a patient's tumor and immune system could enhance the efficacy and safety of MSC-based treatments.” Achieving this requires a deeper understanding of how MSCs interact with cancer cells and their surrounding environment. In conclusion, this review highlights both the potential and challenges of (MSCs in cancer therapy. With ongoing research and technological advancements, MSCs could become a key component of personalized cancer treatments, offering new hope for patients worldwide. DOI - https://doi.org/10.18632/oncotarget.28672 Correspondence to - Feng Lin - flin@curescience.org Video short - https://www.youtube.com/watch?v=Wwc3zDDitlc Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Franco Kraiselburd — Co-Founder and CEO of Asclepii — building the next generation of tissue engineering therapeutics for wound healing.I've recently heard a life's work described as a lifelong quest to build something for others that expresses who you are. It feels to me that Franco is not just building a company, but has found his life's work and is truly pursuing a grand mission.Grounded in an international childhood living across the United States, Spain, Brazil, Argentina and Chile, Franco began his scientific career at the early age of 12, and has spent the last 9 years dedicating his life to the development of accessible and impactful advanced medical devices, translating the ideas from several different labs within the Tissue Engineering field into reality and the market.After 5 years working in the University of São Paulo (Brazil), Franco moved to Cleveland, OH, to work in the Regenerative Medicine field as a Biomedical Engineering student at Case Western Reserve University with Dr. Arnold Caplan, the Father of Mesenchymal Stem Cells and the very person who's research had inspired him to set off down this path in the first place.A scientist and entrepreneur, Franco is constantly trying to bridge the worlds ideas and reality. His wound care innovations are internationally recognized, being awarded a Gold Medal at the 2019 GENIUS Olympiad, nominated for 2025 Forbes Under 30 and MIT Innovators Under 35, and a finalist in the Rising Tech Star category of Ohio's 2023 Best of Tech Awards.Accolades and recognition aside, I can just express personally having gotten to know Franco and listented to him tell his story, that his mind is a wonderful thing to behold and we're lucky to have him as an entreprenuer in Celveland-----LINKS:https://www.linkedin.com/in/francokrais/https://www.asclepii.com/home-----SPONSORS: John Carroll University Boler College of Business || Impact Architects & NinetyJohn Carroll University Boler College of Business: https://business.jcu.edu/ As we've heard time and time again from entrepreneurs on Lay of The Land — many of whom are proud alumni of John Carroll University —  success in this ever-changing world of business requires a dynamic and innovative mindset, deep understanding of emerging technology and systems, strong ethics, leadership prowess, acute business acumen… all qualities nurtured through the Boler College of Business!With 4 different MBA programs of study — spanning Professional, Online, Hybrid, and 1-Year-Flexible — The Boler College of Business provides flexible timelines and various class structures for each MBA Track — including online, in-person, hybrid and asynchronous — to offer the most effective options for you, in addition to the ability to participate in an elective International Study Tour, providing unparalleled opportunities to expand your global business knowledge by networking with local companies overseas and experiencing a new culture.The career impact of a Boler MBA is formative and will help prepare you for this future of business and get more out of your career. To learn more about John Carroll University's Boler MBA programs, please go to business.jcu.eduThe Boler College of Business is fully accredited by AACSB International, the highest accreditation a College of Business can have.Impact Architects & NinetyLay of The Land is brought to you by Ninety. As a Lay of The Land listener, you can leverage a free trial with Ninety, the platform that helps teams build great companies and the only officially licensed software for EOS® — used by over 7,000 companies and 100,000 users!This episode is brought to you by Impact Architects. As we share the stories of entrepreneurs building incredible organizations throughout NEO, Impact Architects helps those leaders — many of whom we've heard from as guests on Lay of The Land — realize their visions and build great organizations. I believe in Impact Architects and the people behind it so much, that I have actually joined them personally in their mission to help leaders gain focus, align together, and thrive by doing what they love! As a listener, you can sit down for a free consultation with Impact Architects by visiting ia.layoftheland.fm!-----Stay up to date by signing up for Lay of The Land's weekly newsletter — sign up here.Past guests include Justin Bibb (Mayor of Cleveland), Pat Conway (Great Lakes Brewing), Steve Potash (OverDrive), Umberto P. Fedeli (The Fedeli Group), Lila Mills (Signal Cleveland), Stewart Kohl (The Riverside Company), Mitch Kroll (Findaway — Acquired by Spotify), and many more.Connect with Jeffrey Stern on LinkedIn — https://www.linkedin.com/in/jeffreypstern/Follow Jeffrey Stern on X @sternJefe — https://twitter.com/sternjefeFollow Lay of The Land on X @podlayofthelandhttps://www.jeffreys.page/

Do you know that you can repair your body and boost longevity without resorting to invasive surgeries?In this episode of The Happy Hustle Podcast, I had the pleasure of chatting with Eric Stoffers, the founder and CEO of BioXcellerator, and let me tell you, this conversation is a game-changer!Eric breaks down the magic behind stem cell therapy, and if you're like me, you'll be amazed at how these tiny building blocks of life can do wonders for your body. Imagine healing and regenerating your body naturally—sounds pretty wild, right? Well, it's not just a dream; it's reality.We dive deep into what makes stem cells so powerful, especially the mesenchymal stem cells sourced from umbilical cords. These little guys have the potential to transform lives, and Eric explains how they're used at BioAccelerator to provide personalized healing protocols. It's not just about the stem cells, though; BioXcellerator takes a holistic approach, incorporating additional therapies like ozone therapy and cryotherapy to maximize results.If you're curious about trying stem cells yourself, you can get 10% off by using code HAPPY when you go through the process at BioXcellerator. Just head over to bioxcellerator.com to learn more and set up a quick consultation.And for entrepreneurial couples out there, listen up! We're hosting a Medellin Mastermind from September 28th to October 5th, 2024. It's a combo of relationship-building on the front end and intense wellness on the back end, with all the top-notch treatments at BioXcellerator. This isn't just a trip; it's a transformative experience for you and your partner. If you want to check out, you can head over to https://thehappyhustle.com/medellin/ Connect with Erichttps://www.instagram.com/ericstoffers.ceo/https://www.facebook.com/bioXcelleratorhttps://www.youtube.com/channel/UC_yiTadTsEbZzhpQOPHRj1ghttps://www.linkedin.com/company/bioxcellerator.com/Find Eric on this website: https://www.bioxcellerator.com/ Connect with Cary!https://www.instagram.com/cary__jack/https://www.facebook.com/SirCaryJackhttps://www.linkedin.com/in/cary-jack-kendzior/https://twitter.com/thehappyhustlehttps://www.youtube.com/channel/UCFDNsD59tLxv2JfEuSsNMOQ/featured Get a free copy of his new book, The Happy Hustle, 10 Alignments to Avoid Burnout & Achieve Blissful Balance (https://www.thehappyhustlebook.com/)Sign up for The Journey: 10 Days To Become a Happy Hustler Online Course (http://www.thehappyhustle.com/Journey)Apply to the Montana Mastermind Epic Camping Adventure (https://caryjack.com/montana)“It's time to Happy Hustle, a blissfully balanced life you love, full of passion, purpose, and positive impact!”Episode sponsor Feeling Stressed? This One Mineral Could Change Your Life!Struggling to keep up with daily demands? Discover the game-changing power of magnesium, the body's "master mineral." It supports over 600 vital reactions, from hormone balance to stress management, sleep, and digestion.Here's the catch: most supplements offer only 1 or 2 forms of magnesium, but your body needs 7! That's why I swear by Magnesium Breakthrough by BIOptimizers (https:// magbreakthrough.com/happyfree), the only supplement with all 7 forms. It's boosted my sleep, reduced my stress, and balanced my life.For a limited time, you can get a FREE bottle of Magnesium Breakthrough (https:// magbreakthrough.com/happyfree) just for you! Grab yours now before supplies run out.

Stem cell therapy helps assist the body's natural ability to repair and regenerate. The intelligence that created us can help us heal and thrive!The field of stem cell therapy has gone through exponential growth in the last few decades. Numerous scientific studies from around the world have demonstrated the ability of stem cells (esp. Mesenchymal Stem Cells, a.k.a. MSC's) to calm inflammation, modulate the immune system, enhance tissue blood supply, break down scar tissue, fight microbes and cancerous cells, protect vulnerable tissue adjacent to damaged areas, and promote local cellular regeneration.To Connect With Dr. Joy Kong:http://drjoykong.com/Watch Video Episodes on YouTube:https://www.youtube.com/channel/UCZj1GQBWFM5sRAL0iQfcMAQFollow Dr. Joy Kong on Social Media:https://www.instagram.com/dr_joy_kong/https://www.facebook.com/stemcelldrjoyhttps://www.linkedin.com/in/joy-kong-md-4b8627123/For more information about anti-aging regenerative medicine treatment visit:https://uplyftcenter.com *Our content is for informational purposes only and should not be treated as medical or health advice. Please consult with your doctor / healthcare provider if you have any questions about your medical conditions.*

Discover cutting-edge advancements in veterinary medicine as we unravel the therapeutic powers of mesenchymal stem cells (MSCs) with the expertise of Dr. Lauren Schnabel. Dive into the intricacies of tendon lesion treatments in horses, a beacon of hope for reducing re-injury rates, and glean insights into the broader applications of MSCs that could transform recovery protocols across different species. Lauren's invaluable research, featured in JAVMA and AJVR, paves the way for groundbreaking localized stem cell therapy, promising a leap forward in veterinary medicine.JAVMA article: https://doi.org/10.2460/javma.23.07.0388 AJVR article: https://doi.org/10.2460/ajvr.23.07.0154INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

LeHeal Biogenix is committed to giving back to the community and supporting those in need. That commitment has prompted them to join forces with The Brothers In Arms Foundation and Regenative Labs to provide much-needed services to veterans in the Tampa Bay Area. Through this donation campaign, the clinic hopes to make a positive impact on the lives of our veterans by providing healthcare services that address pain from damaged tissue. "We are honored to be a part of this initiative to give back to our veterans who have given so much for our country," said LeHeal Biogenix provider Gavril Green Goodman, APRN (Combat Veteran and Flight Nurse with U.S. Air Force). The donation campaign is open to all Marine Special Forces and Recon veterans in the Tampa Bay area who are in need of healthcare services to treat missing or damaged tissue. Instead of covering up the pain with steroids, this type of care addresses the real tissue issue. Veterans interested in receiving healthcare services from LeHeal Biogenix can contact Regenative Labs for more information by calling 1-800-891-3452 x1700 or e-mailing info@regenativelabs.com. LeHeal Biogenix in Tampa, Lakewood Ranch, and Lakeland, Florida, offers innovative pain treatments using the latest medical advances. The practice's biomedical approach uses substances like stem cells and platelet-rich plasma, collectively known as regenerative medicine. LeHeal Biogenix provides a nonsurgical approach to healing and long-lasting pain relief. The medical team specializes in therapies that stimulate the body's natural healing processes. Through orthobiologics (regenerative orthopedics), their treatments stimulate growth factors and reduce inflammation, promoting a faster recovery and improved pain reduction. Regenerative medicine treatments are also safe for repeated use (unlike steroids), offering an alternative treatment for joint pain. These natural substances repair or reduce tissue damage at the injury site, delivering long-lasting pain relief. The treatments LeHeal Biogenix uses cause little discomfort and are outpatient, same-day procedures. South Tampa; Hyde Park Tampa 2007 W Swann Ave, Suite B Tampa, FL 33606 813-999-2192 Brandon 1155 Nikki View Dr, Brandon, FL 33511 813-999-2192 Lakeland 1826 N Crystal Lake Drive, Lakeland, FL 33801 863-249-4744 Lakewood Ranch 8430 Enterprise Cir, Suite 120 Lakewood Ranch, FL 34202 941-909-6011

In this podcast, EIC Josie Briggs talks with Giuseppe Remuzzi about the NEPHSTROM Trial & the next steps in translational work to test the possibility that mesenchymal stem cells can be used as a therapeutic agent to promote repair of kidney damage.

To bring us into the future of stem cells in aesthetics, regenerative medicine pioneer Dr. Steve Cohen joins Dr. Bass for a conversation about the future of this innovative area of medicine.  Because stem cells are not fully differentiated, they have the ability to turn into a muscle cell, a skin cell, or a blood vessel lining cell. This versatility allows them to be used in plastic surgery, where benefits include improving blood supply, making new blood supply, reducing inflammation, and repairing tissue, to name a few. In the future, stem cells might be used for such applications as rehabilitating the tissue during breast reconstruction before putting a breast implant in, healing or reversing radiated tissue in head and neck cancer patients, or in combination with laser treatments for the best possible skin resurfacing results.  Dr. Cohen and Dr. Bass share how stem cells can be incorporated today to get ideal results and how they might help reduce the complexity of procedures and increase longevity of results in the future.   About Steve Cohen, MD Dr. Steve Cohen is a San Diego-based and internationally recognized plastic surgeon, inventor, author, artist, and founder of FACES+. He currently specializes in cosmetic and craniofacial surgery. Learn more about Dr. Cohen's practice, FACES+  https://www.facesplus.com/  Read more about Dr. Steve Cohen  https://www.facesplus.com/about/dr-steven-cohen/   About Dr. Lawrence Bass Innovator. Industry veteran. In-demand Park Avenue board certified plastic surgeon, Dr. Lawrence Bass is a true master of his craft, not only in the OR but as an industry pioneer in the development and evaluation of new aesthetic technologies. With locations in both Manhattan (on Park Avenue between 62nd and 63rd Streets) and in Great Neck, Long Island, Dr. Bass has earned his reputation as the plastic surgeon for the most discerning patients in NYC and beyond. To learn more, visit the Bass Plastic Surgery website or follow the team on Instagram @drbassnyc Subscribe to the Park Avenue Plastic Surgery Class newsletter to be notified of new episodes & receive exclusive invitations, offers, and information from Dr. Bass.   

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.04.22.537784v1?rss=1 Authors: Majumder, A., Joshi, R., Mukherjee, S., Suryawanshi, T., Shukla, S. Abstract: Human mesenchymal stem cells (hMSCs) are multipotent cells that can differentiate into adipocytes, chondrocytes and osteoblasts. Due to their differentiation potential, hMSCs are among the most frequently used cells for therapeutic applications in tissue engineering and regenerative medicine. However, the number of cells obtained through isolation alone is insufficient for hMSC-based therapies and basic research, necessitating their in-vitro expansion. Conventionally, this is often carried out on rigid surfaces such as tissue culture petriplates (TCPs). However, during in-vitro expansion, hMSCs lose their proliferative ability and multilineage differentiation potential, making them unsuitable for clinical use. Although multiple approaches have been tried to maintain hMSC stemness over prolonged expansion, finding a suitable culture system to achieve this remains an unmet need. Recently, few research groups including ours have shown that hMSCs maintain their stemness over long passages when cultured on soft substrate. In addition, it has been shown that hMSCs cultured on soft substrates have more condensed chromatin and lower levels of histone acetylation compared to those cultured on stiff substrates. It has also been shown that condensing/decondensing chromatin by deacetylation/acetylation can delay/hasten replicative senescence in hMSCs during long-term expansion on TCPs. However, how chromatin condensation/decondensation influences nuclear morphology and DNA damage - which are strongly related to the onset of senescence and cancer - is still not known. To answer this question, here we cultured hMSCs for long duration (P4-P11) in presence of epigenetic modifiers histone acetyltransferase inhibitor (HATi) which promotes chromatin condensation by preventing histone acetylation and histone deacetylase inhibitor (HDACi) which promotes chromatin decondensation and investigated their effect on various nuclear markers related to senescence and cancer. We have found that consistent acetylation causes severe nuclear abnormalities whereas chromatin condensation by deacetylation helps in safeguarding nucleus from damages caused by in-vitro expansion. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.03.30.534618v1?rss=1 Authors: Govindaraj, K., Kannan, S., Karperien, M., Post, J. N. Abstract: The multi-lineage differentiation capacity of human mesenchymal stem cells (hMSCs) enables its potential for tissue engineering and regenerative medicine. Master transcription factors play a key role during development, differentiation, homeostasis and disease pathology. RUNX2 is the master transcription factor for bone development, and it regulates several important signaling pathways during chondrogenic and osteogenic differentiation of hMSCs. However, modulation of RUNX2 activity during hMSC differentiation into various lineages is not yet fully described. We differentiated hMSCs into chondro-, osteo-, and adipogenic lineages and studied RUNX2 protein dynamics using Transcription Factor - Fluorescence Recovery After Photobleaching (TF-FRAP) at different time points. The TF-FRAP method can capture the dynamic changes of RUNX2 protein mobility at the single cell level resolution, and cluster analysis shows how RUNX2 dynamics change at subpopulation level in proliferating and differentiating hMSCs. Our data show that although whole hMSC population is exposed to differentiation stimuli, some subpopulations in hMSCs do not respond to environmental cues. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

In this podcast, we dive into our inner geek and talk all about biological therapy and how it is the future of living stronger longer and ageing with agency.  Our guest this week is Dr Konrad Slynarski, an internationally recognised orthopaedic specialist and pioneer in using cell and biological therapies for bone and skeletal health.   It is well known that being active is the key to living stronger for longer, yet as we age we are more at risk of osteoarthritis and other types of aches and pains that can inhibit our activity and even stop us from doing the sport we love. The conventional approach to these issues has been painkillers or anti-inflammatory medication until the problem is so bad it requires a knee or hip replacement. Dr Konrad explains how all that has changed with the advent of injectable cell and biological treatments which can maintain our joints optimally.  What's so exciting about these therapies is that they engage the body's potential to heal itself. They resolve the issue of ageing joints, rather than simply dealing with the symptoms.  At about 30 mins in – there is a dialogue about the male / female difference in the experience of pain that Dr Konrad sees.  Plus, we look at how nutrition and lifestyle can optimise the impact of these biological therapies. You can contact Dr Konrad directly on dr@slynarski.pl  Or via  zuzanna@theregenerativeclinic.co.uk at  www.theregenerativeclinic.co.uk   Dr Konrad's bio:   Dr. Slynarski completed his MD and Ph.D. degrees at The Medical University of Warsaw, Poland, and completed research fellowships at Case Western University in Cleveland, USA, with Prof. Arnold Caplan on Mesenchymal Stem Cells - based cartilage repair (funded by the Polish-American Kosciuszko Foundation), and also with Prof. Matts Brittberg, Sweden. He subsequently completed a knee fellowship with Prof. Rene Verdonk, Belgium. He was a principal investigator in several comprehensive clinical studies on osteoarthritis, cartilage repair, osteotomy, medial knee load-absorber and patello-femoral unloading.  He works on development and improvement of knee joint preservation procedures, including osteotomy and cell-based therapies for cartilage repair. He organized several symposia and courses in the field of cartilage repair, including Warsaw ICRS World Congress in 2007, Polish Arthroscopy Society Congresses and Warsaw Joint Preservation Congress. Dr. Slynarski was Head of several private sports medicine centers in Warsaw.  He was a President od Polish Arthroscopy Society, member of Education Committee of International Cartilage Repair Society (ICRS), Cartilage Committee, Meniscus Committee and Osteotomy Committee of European Society for Sports Traumatology, Knee Surgery, and Arthroscopy (ESSKA).

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.02.03.527029v1?rss=1 Authors: Kong, W., Wang, H., Zhu, X., Han, X. Abstract: Background: Although mesenchymal stem cells (MSCs) are most commonly used in cell therapy and stem cell research, the mechanism and the locations of their self-renewal are still unknown. Method: Mouse blood was collected, and examined under microscopy. The results were compared with the data of human umbilical cord blood (hUCB) collected 10 years ago. Results: We found that the procedure of self-renewal for the mesenchymal stem cells in mouse blood and hUCB needs at least 5 steps. First, tube-shaped stem cell niches release long segmented materials composed of sand-like particles and semitransparent granules. Second, the sand-like particles and semitransparent granules separate from the segmented materials. Third, each of the individual semitransparent granules releases groups of fusiform-shaped structures that do not stain to H&E. The sizes of the fusiform-shaped structures range from 1 to 100 m in length in mouse blood, but can be 200 m in hUCB. Fourth, the large-sized fusiform structures can directly transform into lineage-restricted cellular structures; the medium-sized fusiform structures fuse or engulf each other to form cellular structures. The cellular structures further acquire membranes from the adjacent nucleated cells. Fifth, the nucleolus appears in the new cellular structures before the nucleus. During all the procedures, the adjacent nucleated mesenchymal cells are must needed. Thus, these newly formed cellular structures will further differentiate into nucleated mesenchymal stem cells. Conclusion: Our findings again provide new evidence that, in physiological conditions, mesenchymal stem cell self-renewal needs several steps to complete, which, however, does not occur by mitotic division. The tube-shaped structures are the niches of the stem cells. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Do you want to discover your greatest potential?In this episode of the Happy Hustle Podcast, I have Dr. Kristin Comella, a world-renowned expert on regenerative medicine with a focus on adipose (fat) derived stem cells. We talk about regenerative medicine, reversing chronic disease, and human betterment. Dr. Kristin was named number 24 on Terrapin's list of the Top 50 Global Stem Cell Influencers and number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Most recently, Dr. Comella made the list of Top 50 Functional and Integrative Medical Doctors/Scientists in the country by DrAxe.com, one of the most visited natural health websites in the world. She has more than a dozen peer-reviewed publications indexed on Pubmed in the field of regenerative medicine.She has an extensive background in the study and implementation of biohacking and stem cell therapy. With an engineering background focusing on the mechanics and systems of the body in order to achieve optimal health, her more than 20+ years experience has given her notable training with experts in the stem cell arena. Her graduate studies and coursework at Ohio State University provided her the opportunity to work with Dr. Jeffery Chalmers to focus on the use of nano-particle magnets to isolate/separate cells. She then delved more deeply into stem cell research at Osiris Therapeutics — a small start-up in Maryland — co-founded by the ‘father of Mesenchymal Stem Cells,' Dr. Arnie Caplan. Following her work at Osiris, Dr. Comella was offered the opportunity to work with Dr. Darwin Prockop, the Grandfather of cellular therapy research on mesenchymal progenitors, at Tulane University.For a limited time, Dr. Kristin is offering a free red light treatment just for the Happy Hustlers, you can sign up here at https://infiniteimpacthealth.com/contact/

A review of the evidence   David Rosenblum, MD reviews the description and evidence provided by Loibi et al in the published article referenced below.  Dr. Rosenblum discusses personal experiences with treating back pain with regenerative medicine procedures.  Discussed in this podcast: Patient selection Pathophysiology Environment of the disc and it's impact on MSCs Risks and safety concerns of Intervertebral mesenchymal stem cell transplantation Pain relief and recommendations for MSC injection into the disc in patients suffering from discogenic pain     Claim CME Credit The CE experience for this Podcast is powered by CMEfy - click here to reflect and earn credits: https://earnc.me/WAltmH     Course Calendar     Ultrasound Training Dominican Republic- November 12, 2022   Physician Networking Event- November 17, 2022   Ultrasound Training NYC- December 3, 2022   Regenerative Interventional Pain Course January 28th, 2023   Ultrasound Training Costa Rica- February 29, 2023   Pain Management Board Review and Refresher, June 10-12, 2023- NYC Location TBA  Reserve a spot!     References   Loibl, M,  Wuertz-Kozak, K,  Vadala, G,  Lang, S,  Fairbank, J,  Urban, JP.  Controversies in regenerative medicine: Should intervertebral disc degeneration be treated with mesenchymal stem cells? JOR Spine. 2019; 2:e1043. https://doi.org/10.1002/jsp2.1043

Today we talk with Nurse Practitioner Barb Hopkins. She has been an NP for over 20 years, starting her career in emergency medicine to a helicopter nurse, to helping patients with regenerative medicine. We talk about the difference between steroid injections, PRP and Mesenchymal Stem Cells. She give us a breakdown on how to prepare for these types of treatments and how to optimize results. To learn more about Barb Hopkins or to book a consultation, visit www.egodefined.com You can always call Ego Wellness at 209-577-2799. To learn more about our podcast visit us on TikTok @awakenyourego or on Instagram @_egowellness @_egobeauty  @Ego: Beauty & Wellness Defined  Visit us on Facebook here: https://www.facebook.com/egobeautymodestoand https://www.facebook.com/egowellnessmodestoYou can watch this episode on YouTube here: https://youtu.be/uuEjQl1-QZo

We've all heard of stem cells—and the myths that come with them. Stem cell therapy is one of the most miraculous developments in medicine today, but they are controversial because of the misconceptions. Are they from aborted babies? How are they used exactly? Dr. Joy Kong is here to set the record straight.   Dr. Joy Kong is a UCLA trained, triple board certified physician anti-aging and stem cell specialist and educator, and the CEO and founder of the THEA Center for Regenerative Medicine in California. She focuses her efforts on prevention of aging, as well as chronic diseases that no one else has been able to heal. Dr. Kong believes that completely healing can only come from looking at the whole person, mind, body, and soul (which I couldn't agree more with!).  This has allowed Dr. Joy to address the root causes of health issues and lead her patients to a fuller, more vibrant life.  Join us today as we discuss the conditions that stem cell therapy has been approved to treat, what the FDA says, where the cells come from, and more about Mesenchymal Stem Cells. -- Resources: Find Dr. Joy Kong's podcast on https://www.youtube.com/channel/UCZj1GQBWFM5sRAL0iQfcMAQ (YouTube).  Visit http://charaomni.com (charaomni.com) and use the code REBEL10 for 10% off! Visit https://thisishuso.com/rebel (thisishuso.com/rebel) and use the code “REBEL25” to save $25 Do you want more to empower yourself through healthy living? Is your busy lifestyle an obstacle to your health? Join https://www.facebook.com/groups/rebelhealthcoach/ (The Rebel Health Coach community) for the support and knowledge you need for better performance, better business and a better you! https://www.facebook.com/groups/rebelhealthcoach/ (Click here to join The Rebel Health Coach community now.) -- Disclaimer: The activities and research discussed in these podcasts are suggestions only and are only advised to be undertaken following prior consultation with a health or medical professional. Fitness training, nutrition, and other physical pursuits should be tailored to the individual based upon an assessment of their personal needs. -- The Rebel Health Coach Podcast is produced by http://crate.media (Crate Media)

Multiple Sclerosis News Today's multimedia associate, Price Wooldridge, discusses how mesenchymal stem cells can improve functional abilities and promote the remyelination in rodent models of MS, according to a meta-analysis. Plus, reads a column by John Connor, Fall Down, Get Up Again, “Groundhog Day, Groundhog Day, Groundhog Day, Groundhog Day.” Are you interested in learning more about multiple sclerosis? If so, please visit https://multiplesclerosisnewstoday.com =================================== Are you interested in learning more about multiple sclerosis? If so, please visit: https://multiplesclerosisnewstoday.com/ ===================================== To join in on conversations regarding multiple sclerosis, please visit: https://multiplesclerosisnewstoday.com/forums/

Ariff Roose speaks to James Then, Managing Director of CryoCord Sdn Bhd, about Mesenchymal Stem Cells (MSCs). Discussed are where MSCs can be found, what they can do, and their potential to be used in the treatment of Covid-19.

Mesoblast CEO Dr. Silviu Itescu speaks to Lonza about the company’s advanced portfolio of anti-inflammatory allogeneic cellular medicines including remestemcel-L, which is currently being evaluated in a U.S. Phase 3 randomized controlled trial for acute respiratory distress syndrome (ARDS), the principal cause of mortality due to COVID-19 infection.

John Adams sits down with an Ozarks Doctor whose treatment protocol using Mesenchymal Stem Cells is currently being studied by the FDA as a possible treatment for Covid-19.

On this episode, Dr. James Cox takes us on a deep dive into spinal manipulation and its effects on the immune system. James M. Cox, DC, DACBR, FICC, Hon.D.Litt., FACO(H) Dr. Cox is the developer of Cox® Technic Flexion Distraction Manipulation and the proud participant in the on-going federal research projects involving the National University of Health Sciences, Palmer College of Chiropractic Research Center, Loyola Stritch School of Medicine, University of Illinois, University of Iowa, Auburn University, etc. He is a member of the postgraduate faculty of the National University of Health Sciences and has been privileged to speak throughout the world. Resources: About Dr. Cox curriculum vitae  More about Cox® Technic www.coxtechnic.com Find a Back Doctor The Cox 8 Table by Haven Medical References: ·       Medeiros P1,2,3,4, de Freitas RL1,2,3,4,5, Boccella S1, Iannotta M1, Belardo C1, Mazzitelli M1, Romano R1, De Gregorio D6, Coimbra NC2,3,4, Palazzo E1, Maione S1.Characterization of the sensory, affective, cognitive, biochemical, and neuronal alterations in a modified chronic constriction injury model of neuropathic pain in mice. J Neurosci Res. 2019 Aug 8. doi: 10.1002/jnr.24501. [Epub ahead of print] ·       Colombi A1, Testa M2. The Effects Induced by Spinal Manipulative Therapy on the Immune and Endocrine Systems. Medicina (Kaunas). 2019 Aug 7;55(8). pii: E448. doi: 10.3390/medicina55080448. ·       Kedong H1, Wang D2, Sagaram M3, An HS4, Chee A5. Anti-inflammatory effects of interleukin-4 on intervertebral disc cells. The Spine Journal Volume 20, Issue 1, January 2020, Pages 60-68 ·       Chen NF1,2,3, Chen WF1,4, Sung CS5,6, Lu CH2, Chen CL2, Hung HC1,7, Feng CW1,7, Chen CH1,7, Tsui KH8,9,10, Kuo HM11, Wang HD12,13,14, Wen ZH15,16,17, Huang SY18,19. Contributions of p38 and ERK to the antinociceptive effects of TGF-β1 in chronic constriction injury-induced neuropathic rats. J Headache Pain. 2016 Dec;17(1):72. Epub 2016 Aug 19. ·       Nemoto W, Yamada K, Ogata Y, Nakagawasai O, Onodera K, Sakurai H, Tan-No K. Chondroitin sulfate attenuates formalin-induced persistent tactile allodynia. J Pharmacol Sci Aug 5. pii: S1347-8613(16)30091-3. doi: 10.1016/j.jphs.2016.07.009. ·       Kemeny ME. The immune system: the mind-body connection.  Who gets sick and who stays well. Institute for Brain Potential, Po Box 2238, Los Banos Ca 93635 ·       Egorova E1,2, Starinets A1,2, Tyrtyshnaia A1,2, Ponomarenko A1,2, Manzhulo I3,4. Hippocampal Neurogenesis in Conditions of Chronic Stress Induced by Sciatic Nerve Injury in the Rat. Cells Tissues Organs. 2019 Jul 8:1-11. doi: 10.1159/000501236. [Epub ahead of print] ·       Hingert D1, Nilsson J2, Barreto Henriksson H3,4, Baranto A3,4, Brisby H3,4.Pathological Effects of Cortisol on Intervertebral Disc Cells and Mesenchymal Stem Cells from Lower Back Pain Patients. Cells Tissues Organs. 2019 Jul 3:1-12. doi: 10.1159/000500772. [Epub ahead of print] ·       Kedong H1, Wang D2, Sagaram M3, An HS4, Chee A5. Anti-inflammatory effects of interleukin-4 on intervertebral disc cells. The Spine Journal Volume 20, Issue 1, January 2020, Pages 60-68 ·       Glombiewski JA(1), Riecke J, Holzapfel S, Rief W, König S, Lachnit H, Seifart U. Do patients with chronic pain show autonomic arousal when confronted with feared movements? An experimental investigation of the fear-avoidance model. Pain. 2015 Jan 14. ·       Lubelski D1, Thompson NR, Bansal S, Mroz TE, Mazanec DJ, Benzel EC, Khalaf T. Depression as a predictor of worse quality of life outcomes following nonoperative treatment for lumbar stenosis. J Neurosurg Spine. 2014 Dec 19:1-6. ·       Kayhan F1, Albayrak Gezer İ2, Kayhan A3, Kitiş S4, Gölen M5. Mood and anxiety disorders in patients with chronic low back and neck pain caused by disc herniation. Int J Psychiatry Clin Pract. 2015 Nov 2:1-5. [Epub ahead of print] ·       Pillai AG, de Jong D, Kanatsou S, Krugers H, Knapman A, Heinzmann JM, Holsboer F,Landgraf R, Joëls M, Touma C. Dendritic morphology of hippocampal and amygdalar neurons in adolescent mice is resilient to genetic differences in stress reactivity. PLoS One. 2012;7(6):e38971. Epub 2012 Jun 12.

Get ready - this is an episode unlike any other cATalyzing Podcast episodes before!  Ryan attended the 2020 Athletic Trainers' Society of New Jersey annual convention and business meeting, and he's bringing you the key takeaways (along with a slew of live-tweets via @cATalyzingATs and #ATSNJ2020).  In this episode, there are 11 short segments featuring all of the presenters, along with the ATSNJ President and President-elect. One definitely cannot do this fantastic two-day event justice with a 60 minute podcast, but we tried our best! Below is the lineup, topics, and email addresses in case you wish to reach out for further questions! Thanks to the ATSNJ leadership for their support. This episode will definitely be #cATalyzingATs! Kevin Briles - ATSNJ Key Updates and 2020 Initiatives (kbriles@atsnj.org) Jessica Springstead - Making ATSNJ Conference Happen (jspringstead@atsnj.org) Doug Mann, DPE, ATC - Vitamin D Deficiency & its Relationship to Injury, Gender, Race, and Sport Season (mannd@rowan.edu) Jeff Konin, PhD, ATC, PT, FACSM, FNATA - Cannabis as an Intervention for Patient Care (DrJeffKonin@gmail.com) Steve Barandica, MEd, ATC, EMT - What you Need to Know Your First Year as a Professional (barandicas@atsnj.org) Doug Stringham, MS, LAT, ATC - How to Best Build and Utilize your Tool Box (stringhamde@gmail.com) Drue Stapleton, PhD, ATC, CSCS - Movement Quality and Athletic Performance: Does it Matter? (dstapleton@rider.edu) Bradford Tucker, MD - Clinical Efficiency of Intra-articular Mesenchymal Stem Cells for the Tx of Knee OA (bradford.tucker@rothmaninortho.com) Darryl Conway, MA, LAT, ATC - Take A.C.T.I.O.N.: Opioid Overdose Education, Prevention, & Management (datc@umich.edu) Scott Dankel, PhD - BFR: Safety, Application, and Efficacy (dankel47@rowan.edu) William Gallagher, MD - Current Concepts in the Office Based Tx of the Concussed Athlete (william.gallagher@rothmaninortho.com) Visit www.ATSNJ.org for more information on the Athletic Trainers' Society of New Jersey! --- Send in a voice message: https://anchor.fm/catalyzing-podcast/message

On this episode of Anti-Aging Hacks podcast, we discuss: 1. What are Exosomes and how are they different from Mesenchymal Stem Cells 2. How Exosomes lower chronic inflammation and can reduce the incidence of diseases 3. How to use Exosomes in your anti-aging protocol My guest on this podcast episode is Dr. Duncan Ross, who is the founder and CEO of Kimera Labs. Dr. Duncan Ross, Ph.D. is a post-doctoral research scientist in the field of biochemistry, immunology, stem cell culture and exosome technology, who has developed and patented proprietary methods of stem cell manipulation and exosome isolation and purification.

Mesenchymal Stem Cells. Part 2/2. A brief overview of the functions of these cells and how they can be used in medicine now and in the future

This episode is about Mesenchymal Stem Cells. Part 1/2.  A brief overview of the functions of these cells and how they can be used in medicine now and in the future

In this episode of the American Shoulder and Elbow Surgeons Podcast, seven presenters from the 2019 Annual Meeting are interviewed by host Dr. Peter Chalmers with guest hosts.  Author: Dr. Brian Cole Guest Host: Dr. Justin Griffin Title: “Prospective Randomized Trial of Biologic Augmentation with Mesenchymal Stem Cells in Patients Undergoing Arthroscopic Rotator Cuff Repair” Author: Dr. Raffy Mirzayan Guest Host: Dr. Rob Hartzler Title: “Functional and MRI Outcomes of Superior Capsule Reconstruction with Acellular Dermal Matrix”. Author: Dr. Mark Schrumpf Guest Host: Dr. Alex Aleem Title: “Elbow Hemi-Arthroplasty for Intra-Articular Distal Humerus Fractures: Results and Technique” Author: Dr. Shawn O’Driscoll Guest Host: Dr. Brandon Erickson Title: “CT Reveals Additional Important Information for Preoperative Diagnosis of Capitellar Osteochondritis Dissecans Compared to MRI” Author: Dr. Robert Hudek Guest Host: Dr. Eric Ricchetti Title: “Cutibacterium (Propionibacterium) Acnes Is Observed as an Intraarticular and Intracellular Commensal of the Human Shoulder Joint During First-Time Surgery” Author: Dr. Mark Frankle Guest Host: Dr. Jon Barlow Title: “Acute Surgical Management of Proximal Humerus Fractures: ORIF vs. Hemiarthroplasty vs. Reverse Shoulder Arthroplasty” Author: Dr. Rob Hartzler Guest Host: Dr. Brendan Patterson Title: “Radiographic Parameters Associated with Excellent Versus Poor Range of Motion Outcomes Following Reverse Shoulder Arthroplasty”    

Topic Discussed : Global Cell Therapy MarketSpeaker: Aarti ChitaleKey Takeaways:This report covers the key trends and opportunities across the global cell therapy market. Some of the key areas being covered under the market include, industry trends, manufacturing automation, combination therapies and other future trends The report also highlights some of the emerging business models benefiting the market as well as the key drivers and restraints affecting the market growthWith the changing market landscape, Big pharma/bio-pharma players, are looking towards the adoption of a collaborative business approach by either entering into co-development/ co-commercialization agreements or acquiring smaller niche players so as to achieve competitive advantage with respect to specific therapy area or technologyAdditionally, in order to cater to the pricing needs of these high value therapies, the companies are adopting a pay for performance model which allows the payer to make a payment basis the therapeutic outcome of the novel therapyKymriah and yescarta are amongst the first such CAR-T cell therapies with this arrangement. Also, there is a large scale adoption of risk sharing, fast to market models, which supports the development of these novel therapiesFor further insights, please join us for future podcasts and become a member of Frost & Sullivan’s Leadership Council by emailing us at: digital@frost.com or click here to Contact Us.Related Keywords: Frost & Sullivan, Regenerative Medicine, Combination Therapies, Cell-Gene therapies, Stem Cell Therapies, Mesenchymal Stem Cells, Adipose Derived Stem Cells, Induced Pluripotent Stem Cells, European Medicines Agency, Food and Drug Administrations, Act for Safety of Regenerative Medicine, Pharmaceutical and Medical Devices Act, CRISPR/Cas9, ACR-T Cell Therapies, Kymriah, Yescarta, Gilead Sciences, Novartis, Mergers and Acquisitions, Genome Editing, Curative Therapies, Nano-medicine, Alternative payment Models, One-time Payment Model, Annuity Payment Model, Value Based Payment Model, Autologous Stem Cells, Allogeneic Stem Cells, Fast to Market Model, Risk Sharing Model, In-House Development, Competitive Playbook, Conditional Approval, Oncology, Neurology, Cardiovascular Diseases, Dermatology, Muscoloskeletal, ImmunologyWebsite: www.frost.com See acast.com/privacy for privacy and opt-out information.

Today's episode of the Regenerative Warrior Podcast, Dr. Ross Carter and Suzanne Page talks about the delibitating condition that affects over 20 million people in the United States and how mesenchymal stem cells might be able to help eliminate it. They also talked about other mesenchymal stem cell uses and other ongoing MSC related clinical trials. Suzanne also shared some of the methods they're using to help people with aging frailty. We also discussed other potential treatment uses for mesenchymal stem cells outside of aging frailty. ____ To find out more about our guest, become a guest on our show, or if you want Dr. Carter present at your event or podcast, learn more about coaching, consulting, allografts, exosomes, supplements, legal help, or how to create a million dollar business card and dominate your area, we’re here to help you.  Just text your name and question to 561-962-1231 or go to our website at drrosscarter.com to learn more. Thanks for listening! Please subscribe to be notified of all new episodes. You can also like and share each episode to help us grow!

In this episode, I sit down with Dr. Kristin Comella, US Stem Cells' Chief Science Officer. Kristen has an extensive background in the study and implementation of biohacking and stem cell therapy. With an engineering background focusing on the mechanics and systems of the body in order to achieve optimal health, her more than 20+ years experience has given her notable training with experts in the stem cell arena. Her graduate studies and course work at Ohio State University provided her the opportunity to work with Dr. Jeffery Chalmers to focus on the use of nano-particles magnets to isolate/separate cells. She then delved more deeply into stem cell research at Osiris Therapeutics — a small start-up in Maryland — mentored company founded by the ‘father of Mesenchymal Stem Cells,' Dr. Arnie Caplan. Following her work at Osiris, Dr. Comella was offered the opportunity to work with Dr. Darwin Prockop, the Grandfather of cellular therapy research on mesenchymal progenitors, at Tulane University.    Dr. Comella is a world-renowned expert on regenerative medicine with a focus on adipose (fat) derived stem cells. She was named number 24 on Terrapin's list of the Top 50 Global Stem Cell Influencers and number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Most recently, Dr. Comella made the list of Top 50 Functional and Integrative Medical Doctors/Scientists in the country by DrAxe.com, one of the most visited natural health websites in the world. She has more than a dozen peer reviewed publications indexed on Pubmed in the field of regenerative medicine.   Links   Kristin Comella PhD on Facebook https://www.facebook.com/comella.stem.cell/ Dr. Kristin Comella on Instagram https://www.instagram.com/kristincomella U.S. Stem Cell Clinic www.usstemcellclinic.com/biohacks (Save $500 on stem cell treatment) Biohackers Health and Fitness in Weston, FL https://biohackersfitness.com/ (save 20% on any 3-month package just mention this episode or “Biohacking Secrets”) Here's where you can grab your copy of our free book The Biohacker's Guide to Upgraded Energy and Focus (just help with shipping) https://biohackersguide.com/biohackers-guide-free. Learn more about the #1 High Performance Coaching Program in the world and have Anthony personally help you get in the best shape of your life, double your energy, and live in a state of optimal performance www.biohackingsecrets.com/coaching

Can a stem cell serum help Bruce recover faster from a fight with Bane? Find out on this week's episode of School of Batman! This week, we're joined by Mark Hahnel. Mark has a PhD in Stem Cell Mobilisation from Imperial College London. Mark is currently the founder and CEO of Figshare, a repository for non-traditional research outputs. Find out more about Mark's research on Twitter at https://twitter.com/MarkHahnel. You can also find Mark's thesis and data at https://figshare.com/articles/Trafficking_of_Mesenchymal_Stem_Cells/923522. __________________ Impact Moderato by Kevin MacLeod is licensed under a Creative Commons Attribution license (creativecommons.org/licenses/by/4.0/) Source: incompetech.com/music/royalty-fre…isrc=USUAN1100618 Artist: incompetech.com/ Cool Vibes - Film Noire by Kevin MacLeod is licensed under a Creative Commons Attribution license (creativecommons.org/licenses/by/4.0/) Source: incompetech.com/music/royalty-fre…isrc=USUAN1100863 Artist: incompetech.com/ Mechanolith by Kevin MacLeod is licensed under a Creative Commons Attribution license (creativecommons.org/licenses/by/4.0/) Source: incompetech.com/music/royalty-fre…isrc=USUAN1100879 Artist: incompetech.com/

Dr. Steven Victor, is a leader in Regenerative Medicine specializing in Regenerative Cosmetic Dermatology. His experience in researching, developing and providing treatment spans over thirty years. He is a clinical expert in groundbreaking anti­-aging and cellular therapy technologies, with a passion for creating safe, minimally invasive treatments that aid patients in living a longer, healthier, more beautiful life. His reputation for excellence has brought numerous worldwide celebrities, TV personalities and models to his practice. Most recently and most notably, Dr. Victor has developed a state-of-the-art laboratory and a patented, proprietary technology for the efficient and reproducible separation of stromal vascular fraction cells containing Mesenchymal Stem Cells, from the vasculature (blood vessels) in adipose (fat) tissue. Medical Practitioner – Dr. Victor received his medical degree from New York Medical College and a Bachelor of Arts degree from NYU. He is Board Certified in Regenerative Medicine by the American Board of Regenerative Medicine. Educator – He has held hospital teaching appointments at New York University, New York Medical College, Beth Israel Medical Center and Lenox Hill Hospital. Respected Expert – Has been featured in international and national media, discussing regenerative medicine, medical aesthetics and cosmetic dermatology, and was the consulting dermatologist to Elizabeth Arden, Medicis Pharmaceuticals and Clarins. Innovator – Dr. Victor has developed a technology in cellular therapy patented for IntelliCell Biosciences and licensed by ReGen Medical, PC. Author – He is also a co­-author of the book Ageless Beauty, A Dermatologist’s Secrets to Looking Younger Without Surgery (2003).

WE ARE BACK FROM BREAK and bringing with us some biologics! When talking biologics like PRP and "stem cells" sloppy research abounds. This reality isn't really fair to anyone trying to find a deeper understanding of what may or may not be going on here. Can we do better with this process? Can physical therapists apply some of these same reporting guidelines to their on research to provide a better "fair test"? Do you find this episode...Bohrium? Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells. Murray IR, Geeslin AG, Goudie EB, Petrigliano FA, LaPrade RF. J Bone Joint Surg Am. 2017 May 17;99(10):809-819. doi: 10.2106/JBJS.16.00793. Due to copyright laws, unless the article is open source we cannot legally post the PDF on the website for the world to download at will. That said, if you are having difficulty obtaining an article, contact us. Music for PT Inquest: "The Science of Selling Yourself Short" by Less Than Jake Used by Permission  

Commentary by Dr. Valentin Fuster

Hematopoietic and Neuronal Cells vs Mesenchymal Cells Many of the companies who promote Stem Cell treatments use Adipose derived Mesenchymal Stem Cells. What this means is that your fat is extracted (in a procedure like liposuction) and then using a method of spinning this material, it separates into its various components and the Stem cells that are in the fat tissue are used.This Mesenchymal Cell has several properties, such as the ability to stimulate the body’s own healing resources; however, it also has limitations such as only being able to change into fat, bone or cartilage- and is classified as multipotent. These cells are also not able to enter into the body’s tissue to do repair and regeneration as they do not possess the proper ligands (coordination entities) to bind to the affected tissue.In contrast, cells that are fetal derived are pluripotent, which means they can become 220 different cell types the body needs for repair and restoration. The Hematopoietic cells can enter into the tissues and do repair and regeneration as well as providing healthy DNA information to halt and reverse the effects of various diseases.The neuronal cells (the fetus is the only source of pure, pristine Neuronal cells) do the same in the brain and nervous system. All of this is possible without matching and with no immunosuppressive drugs required.Visiting on Late Night Health is William Rader, a former doctor who has spent twenty years researching stem cell therapies. He offers treatment for patients with chronic disease including Parkinson's, some cancers, Multiple Sclerosis, Muscular Dystrophy, Cystic Fibrosis and others. Rader lost his California license two years ago and shares the reason for this on the show.With over three thousand patients, Rader notes there are no known side effects from the treatment. Success at reducing symptoms is an amazing 90 plus percent.

Hematopoietic and Neuronal Cells vs Mesenchymal Cells Many of the companies who promote Stem Cell treatments use Adipose derived Mesenchymal Stem Cells. What this means is that your fat is extracted (in a procedure like liposuction) and then using a method of spinning this material, it separates into its various components and the Stem cells that are in the fat tissue are used. This Mesenchymal Cell has several properties, such as the ability to stimulate the body’s own healing resources; however, it also has limitations such as only being able to change into fat, bone or cartilage- and is classified as multipotent. These cells are also not able to enter into the body’s tissue to do repair and regeneration as they do not possess the proper ligands (coordination entities) to bind to the affected tissue. In contrast, cells that are fetal derived are pluripotent, which means they can become 220 different cell types the body needs for repair and restoration. The Hematopoietic cells can enter into the tissues and do repair and regeneration as well as providing healthy DNA information to halt and reverse the effects of various diseases. The neuronal cells (the fetus is the only source of pure, pristine Neuronal cells) do the same in the brain and nervous system. All of this is possible without matching and with no immunosuppressive drugs required. Visiting on Late Night Health is William Rader, a former doctor who has spent twenty years researching stem cell therapies. He offers treatment for patients with chronic disease including Parkinson's, some cancers, Multiple Sclerosis, Muscular Dystrophy, Cystic Fibrosis and others. Rader lost his California license two years ago and shares the reason for this on the show. With over three thousand patients, Rader notes there are no known side effects from the treatment. Success at reducing symptoms is an amazing 90 plus percent.

Hematopoietic and Neuronal Cells vs Mesenchymal Cells Many of the companies who promote Stem Cell treatments use Adipose derived Mesenchymal Stem Cells. What this means is that your fat is extracted (in a procedure like liposuction) and then using a method of spinning this material, it separates into its various components and the Stem cells that are in the fat tissue are used. This Mesenchymal Cell has several properties, such as the ability to stimulate the body’s own healing resources; however, it also has limitations such as only being able to change into fat, bone or cartilage- and is classified as multipotent. These cells are also not able to enter into the body’s tissue to do repair and regeneration as they do not possess the proper ligands (coordination entities) to bind to the affected tissue. In contrast, cells that are fetal derived are pluripotent, which means they can become 220 different cell types the body needs for repair and restoration. The Hematopoietic cells can enter into the tissues and do repair and regeneration as well as providing healthy DNA information to halt and reverse the effects of various diseases. The neuronal cells (the fetus is the only source of pure, pristine Neuronal cells) do the same in the brain and nervous system. All of this is possible without matching and with no immunosuppressive drugs required. Visiting on Late Night Health is William Rader, a former doctor who has spent twenty years researching stem cell therapies. He offers treatment for patients with chronic disease including Parkinson's, some cancers, Multiple Sclerosis, Muscular Dystrophy, Cystic Fibrosis and others. Rader lost his California license two years ago and shares the reason for this on the show. With over three thousand patients, Rader notes there are no known side effects from the treatment. Success at reducing symptoms is an amazing 90 plus percent.

Hematopoietic and Neuronal Cells vs Mesenchymal Cells Many of the companies who promote Stem Cell treatments use Adipose derived Mesenchymal Stem Cells. What this means is that your fat is extracted (in a procedure like liposuction) and then using a method of spinning this material, it separates into its various components and the Stem cells that are in the fat tissue are used.This Mesenchymal Cell has several properties, such as the ability to stimulate the body’s own healing resources; however, it also has limitations such as only being able to change into fat, bone or cartilage- and is classified as multipotent. These cells are also not able to enter into the body’s tissue to do repair and regeneration as they do not possess the proper ligands (coordination entities) to bind to the affected tissue.In contrast, cells that are fetal derived are pluripotent, which means they can become 220 different cell types the body needs for repair and restoration. The Hematopoietic cells can enter into the tissues and do repair and regeneration as well as providing healthy DNA information to halt and reverse the effects of various diseases.The neuronal cells (the fetus is the only source of pure, pristine Neuronal cells) do the same in the brain and nervous system. All of this is possible without matching and with no immunosuppressive drugs required.Visiting on Late Night Health is William Rader, a former doctor who has spent twenty years researching stem cell therapies. He offers treatment for patients with chronic disease including Parkinson's, some cancers, Multiple Sclerosis, Muscular Dystrophy, Cystic Fibrosis and others. Rader lost his California license two years ago and shares the reason for this on the show.With over three thousand patients, Rader notes there are no known side effects from the treatment. Success at reducing symptoms is an amazing 90 plus percent.

This podcast covers the JBJS issue for January 2016. Featured are articles covering Effect of Compliance Counseling on Brace Use and Success in Adolescent Idiopathic Scoliosis; recorded commentary by Dr. Reinker; Addition of Mesenchymal Stem Cells to Autologous Platelet-Enhanced Fibrin in Chondral Defects; Augmented Compared with Nonaugmented Surgical Repair After Total Achilles Rupture - Results of a Prospective Randomized Trial; recorded commentary by Dr. Ebeling; Cost-Effectiveness of Bariatric Surgery Prior to TKA in the Morbidly Obese - A Computer Model-Based Evaluation.

This podcast covers the JBJS issue for January 2016. Featured are articles covering Effect of Compliance Counseling on Brace Use and Success in Adolescent Idiopathic Scoliosis; recorded commentary by Dr. Reinker; Addition of Mesenchymal Stem Cells to Autologous Platelet-Enhanced Fibrin in Chondral Defects; Augmented Compared with Nonaugmented Surgical Repair After Total Achilles Rupture - Results of a Prospective Randomized Trial; recorded commentary by Dr. Ebeling; Cost-Effectiveness of Bariatric Surgery Prior to TKA in the Morbidly Obese - A Computer Model-Based Evaluation.

Michael Matthay and Jennifer Wilson discuss the potential of mesenchymal stem cells for the treatment of ARDS

Major advances in understanding and treating breast cancer have been made in the last two decades, yet it remains a significant problem with breast cancer being the most commonly identified cancer and the leading cause of cancer death among women worldwide. For many years breast cancer research has mainly focused on genetically changed cancer cells. However, recently the importance of the stromal compartment surrounding cancer cells in facilitating tumor growth, invasion and metastasis has been widely recognized. Cumulating evidence suggests that in particular carcinoma-associated myofibroblasts play a key role within the tumor stroma and influence many aspects of carcinogenesis. Nevertheless, the cell type of origin as well as the precise mechanisms by which these cells develop has not been conclusively established and remains controversial. The role of human adipose tissue derived stem cells (hASCs) in this context has not been studied so far. hASCs are locally adjacent to epithelial breast cancer cells and might represent early response cells within the tumor stroma. Hence, the aim of this study was to investigate whether carcinoma-associated myofibroblasts may originate from hASCs. The present study revealed that a significant percentage of hASCs differentiate into myofibroblast-like cells expressing alpha smooth muscle actin (α-SMA) and tenascin-C when exposed to conditioned medium from the human epithelial breast cancer cell lines MDMAB231 and MCF7. This process is induced by transforming growth factor beta 1 (TGFβ1) secreted from breast cancer cells. It was shown that conditioned medium from MDMAB231 and MCF7 contains significant amounts of TGFβ1. It could further be demonstrated that the differentiation of hASCs towards myofibroblasts is dependent on TGFβ1 signaling via phosphorylation of Smad2 and Smad3 in hASCs. The induction of myofibroblasts can be abolished using a neutralizing antibody to TGFβ1 as well as by pretreatment of hASCs with SB431542, a selective inhibitor of the TGFβ1 activin receptor-like kinases 4, 5 and 7. Additionally, hASC-derived myofibroblasts exhibit functional properties of carcinoma-associated myofibroblasts such as the increased secretion of the tumor-promoting soluble factors SDF-1α and CCL5. Furthermore hASC-derived myofibroblasts as well as conditioned medium from these cells promote the in vitro invasion of MDAMB231 breast cancer cells. Moreover inhibition of the TGFβ1 signaling pathway in hASCs reduces the potential of these cells to enhance the invasion of breast cancer cells. Overall, the data of the present study suggest that human adipose tissue derived stem cells can differentiate into carcinoma-associated myofibroblast under the influence of TGFβ1 secreted from breast cancer cells in vitro. The differentiation of hASCs towards these tumor-promoting cells can be abolished by targeting the TGFβ1 signaling pathway. Hence, inhibition of the TGFβ1 signaling pathway may prove to be an interesting target for breast cancer therapies. In vivo studies on the cancer microenvironment under special consideration of the interactions between hASCs and cancer cells should be of interest for breast cancer research in the future.

WFIRM talks to Arnold Caplan, PhD about Mesenchymal Stem Cells.

Join Dr. Vicki Thayer, President of the Winn Feline Foundation, as she interviews Dr. Carol Reinero at the June 2013 ACVIM meeting about current research into the use of mesenchymal stem cell therapy for asthma in cats. Dr. Reinero is a veterinary clinical scientist and associate professor located with the veterinary teaching hospital at the University of Missouri in Columbia. Dr. Reinero was part of the research team from MU funded by Winn Feline Foundation in 2011, 2012, and earlier in 2013 to study the use of  mesenchymal stem cells in cats with asthma. Stem cell therapy is a new frontier in treatment and the Winn Feline Foundation has been on the cutting edge by funding cat health studies in this area. Dr. Reinero discusses the current state of treatment of asthma in cats and the potential future use of mesenchymal stem cells for this disease.

Dr Essex talks to ecancetv at the 14th International Myleoma Workshop, Kyoto, Japan, 3-7th April 2013. Multiple myeloma (MM) plasma cells co-cultured with stroma taken from MM bone marrow demonstrates that it is the stroma, rather than the plasma cell, that acts as a major determinant of disease progression in MM. The role of bone marrow mesenchymal stem cells (BMMSC) in the progression of MM and monoclonal gammopathy of undetermined significance (MGUS) was investigated. BMMSC were isolated from control, MGUS and MM bone marrow. The full genetic profile of these cells was examined using microarrays, with detailed pathway analysis to determine the genes involved in disease progression. 30 patients BMMSC were analysed using U133 plus 2.0 GeneChip microarrays; this highlighted 187 genes that had over a 1.5 fold difference in expression between control and disease BMMSC. Pathway analysis of these genes generated several differentially expressed pathways, with Wnt signalling being the most evident. Two Wnt pathway genes whose expression is significantly decreased in disease BMMSC are secreted frizzled-related proteins (sFRPs) 2 and 4. This decrease in expression was confirmed by RT-PCR, with a concurrent increase in methylation status suggesting these genes have become epigenetically silenced. Splice variant analysis of these particular genes showed a differential expression of exons, which may be functionally significant for Wnt signalling. For the first time Dr Essex's team showed profound silencing of negative regulators of Wnt signalling within MM and MGUS BMMSC, which may help to design early interventions aimed at patients in the premalignant state.

MONDAY, July 23, 2012 - 3:30 pm PST/6:30 pm EST BACK BY POPULAR DEMAND - Our incredible special guest is Jan A. Nolta, Ph.D., the Director of the Stem Cell Program at UC Davis School of Medicine, and directs the new Institute for Regenerative Cures. The UC Davis stem cell program has over 150 faculty members collaborating to work toward stem cell-related cures for a spectrum of diseases and injuries.   Dr. Nolta's laboratory focuses on “bench to the bedside” research, and she has been involved in numerous clinical trials of cell therapy. In 1994 she developed her passion for cellular therapy by assisting with the first umbilical cord blood stem cell gene therapy trials for newborns with “bubble baby disease”, with her mentor Donald Kohn at Children's Hospital of Los Angeles.   A scientist with more than 20 years' experience with human stem cells, Dr. Nolta has published over 100 manuscripts in the stem cell field and has authored 25 book chapters. She has served on over 200 grant review panels for the National Institutes of Health and other agencies, is Editor for the Journal “Stem Cells” and was editor of the Book "Genetic Engineering of Mesenchymal Stem Cells".   Dr. Nolta is a native of northern California and is extremely happy to be back in the area, since being recruited back to UC Davis from Washington University in 2007. The opportunity to help enhance stem cell research and development of therapies in her native Northern California was one of the leading draws to bring her back to the state.  www.jannolta.comwww.EndHD.org  

Mon, 9 Jul 2012 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/14599/ https://edoc.ub.uni-muenchen.de/14599/1/Bao_Qi.pdf Bao, Qi

Thu, 24 May 2012 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/14385/ https://edoc.ub.uni-muenchen.de/14385/1/Pappou_Emmanouil.pdf Pappou, Emmanouil ddc:610, dd

Monday, March 12, 2012 Our incredible special guest is Jan A. Nolta, Ph.D., the Director of the Stem Cell Program at UC Davis School of Medicine, and directs the new Institute for Regenerative Cures. The UC Davis stem cell program has over 150 faculty members collaborating to work toward stem cell-related cures for a spectrum of diseases and injuries. Dr. Nolta's laboratory focuses on “bench to the bedside” research, and she has been involved in numerous clinical trials of cell therapy. In 1994 she developed her passion for cellular therapy by assisting with the first umbilical cord blood stem cell gene therapy trials for newborns with “bubble baby disease”, with her mentor Donald Kohn at Children's Hospital of Los Angeles. A scientist with more than 20 years' experience with human stem cells, Dr. Nolta has published over 100 manuscripts in the stem cell field and has authored 25 book chapters. She has served on over 200 grant review panels for the National Institutes of Health and other agencies, is Editor for the Journal “Stem Cells” and was editor of the Book "Genetic Engineering of Mesenchymal Stem Cells". Dr. Nolta is a native of northern California and is extremely happy to be back in the area, since being recruited back to UC Davis from Washington University in 2007. The opportunity to help enhance stem cell research and development of therapies in her native Northern California was one of the leading draws to bring her back to the state.

Wnt/β-catenin signaling is of fundamental importance in the regulation of self-renewal, migration/invasion, and differentiation of human mesenchymal stem cells (hMSCs). Because little information is available about the function of Frizzled receptors (Fzds) as the main receptors of Wnt proteins in hMSCs, we first performed comparative Fzd mRNA expression profiling. Fzd9 and Fzd10 were not expressed in hMSCs. While Fzd3 was expressed at low levels in hMSCs, the other Fzds exhibited high expression rates. Activation and repression of Wnt signaling in hMSCs revealed that the expression levels of Fzd1, Fzd6, and Fzd7 are positively correlated with the Wnt/β-catenin activation status, whereas Fzd8 exhibited an inverse relation. For studying the functional relevance of Fzds in Wnt/β-catenin signaling, RNA interference, ectopic expression studies, and rescue approaches were performed in hMSCs carrying a highly sensitive TCF/LEF reporter gene system (Gaussia luciferase). We found that, Fzd1, Fzd5, Fzd7, and Fzd8 are largely involved in Wnt/β-catenin signaling of hMSCs. Moreover, the knockdown of Fzd5 can be compensated by the ectopic expression of Fzd7. Conversely, the ectopic expression of Fzd5 in Fzd7-knockdown hMSCs resulted in a rescue of Wnt/β-catenin signaling, pointing to a functional redundancy of Fzd5 and Fzd7.

Osteogenic repair in response to bone injury is characterized by activation and differentiation of mesenchymal stem cells (MSCs) to osteoblasts. This study determined whether activation of Sirt-1 (a NAD(+)-dependent histone deacetylase) by the phytoestrogen resveratrol affects osteogenic differentiation. Monolayer and high-density cultures of MSCs and pre-osteoblastic cells were treated with an osteogenic induction medium with/without the Sirt-1 inhibitor nicotinamide or/and resveratrol in a concentration dependent manner. MSCs and pre-osteoblastic cells differentiated to osteoblasts when exposed to osteogenic-induction medium. The osteogenic response was blocked by nicotinamide, resulting in adipogenic differentiation and expression of the adipose transcription regulator PPAR-γ (peroxisome proliferator-activated receptor). However, in nicotinamide-treated cultures, pre-treatment with resveratrol significantly enhanced osteogenesis by increasing expression of Runx2 (bone specific transcription factor) and decreasing expression of PPAR-γ. Activation of Sirt-1 by resveratrol in MSCs increased its binding to PPAR-γ and repressed PPAR-γ activity by involving its cofactor NCoR (nuclear receptor co-repressor). The modulatory effects of resveratrol on nicotinamide-induced expression of PPAR-γ and its cofactor NCoR were found to be mediated, at least in part, by Sirt-1/Runx2 association and deacetylation of Runx2. Finally, knockdown of Sirt-1 by using antisense oligonucleotides downregulated the expression of Sirt-1 protein and abolished the inhibitory effects of resveratrol, namely nicotinamide-induced Sirt-1 suppression and Runx2 acetylation, suggesting that the acetylated content of Runx2 is related to downregulated Sirt-1 expression. These data support a critical role for Runx2 acetylation/deacetylation during osteogenic differentiation in MSCs in vitro. (242 words in abstract).

Introduction: Human mesenchymal stem cells (hMSC) are easily obtainable from bone mar-row and possess the ability to differentiate into osteoblasts. Therefore, they have been sug-gested as a suitable source for bone regeneration. HMSC are equipped with a variety of in-tegrins that mediate essential cell-matrix interactions. Collagen I represent approximately 90% of the bone protein content. Cell attachment to collagen I is mediated by three members of the integrin receptor family named a1b1, a2b1 and a11b1 integrins. The main aim of this doctoral thesis was to investigate the basal expression of those integrins in hMSC and to func-tionally analyze the knockdown effect of a single collagen I-binding integrin on hMSC behav-ior in vitro. Materials and methods: HMSC were cultured on collagen I-coated surface. A lentiviral trans-fer of a1-, a2- and a11-specific shRNA was applied for downregulation of the corresponding integrin mRNA. Quantitative PCR and western blot analysis were used to assess the basal ex-pression, knockdown efficiency and integrin compensation. Colorimetric adhesion assay was used for estimation of the extent of cells attachment. HMSC spreading and migration was ob-served by time lapse experiments. JC-1 staining was used for investigation of the initiation of apoptosis. Results: Quantitative PCR were used to assess the basal expression of collagen I-binding integrins in three hMSC donors. We found that these integrins are differently expressed as integrin a11 had the highest and integrin a2 the lowest expression. Next, we applied lentiviral delivery of target-specific short hairpin RNA (shRNA) in order to knockdown each of the collagen I-binding integrins and compared them to the hMSC transduced with a sequence against a non-human gene abbreviated as shRNA control. We achieved significant downregulation (> 80%) of the collagen I-binding integrin mRNA and protein. Subsequently to the transduction, we did not noticed pronounce morphological cell changes, however, a clear decrease of a2- and a11-knockdown hMSC numbers was observed during cultivation. Using a quantitative adhesion assay, we estimated that 120 min after plating only 30% of integrin a11-deficent cells were able to attach to collagen I. In contrast, at the same time point, 70% of integrin a2-knockdown hMSC were attached while integrin a1- and shRNA control hMSC have already reached 100% cell adhesion. Furthermore, a time lapse-based investigation showed that integrin a1- and shRNA control hMSC need approximately 35 min to fully spread on collagen I. In contrast, integrin a2- and a11-knockdown hMSC took approximately double more time for spreading in comparison to shRNA control hMSC. Additionally, we analyzed the migration capability of the four different hMSC lines. The average path which integrin a1- and shRNA control hMSC passed was approximately 170 µm with mean speed of 11.5 µm/h. In parallel integrin a2 and a11-deficient hMSC migrated to a distance of approximately 70 µm with a velocity of 5 µm/h. Since it was observed a lost of a2- and a11-deficient hMSC, next we performed JC-1 staining that visualizes mitochondrial leakage, a hallmark of apoptosis. The majority of integrin a2- and a11-knockdown hMSC exhibited mitochondrial leakage whereas integrin a1- and shRNA control hMSC showed intact mitochondria. Finally, we used quantitative PCR to investigate whether there were compensatory effects between the three integrin receptors. We detect that knockdown of integrin a1 led to upregulation of a2 and a11. Similarly, when integrin a2 was downregulated, integrin a1 and a11 expression increased. Interestingly, knockdown of integrin a11 caused only a slight increase in integrin a1 but not in a2 expression. We also observed that upon osteogenic stimulation, integrin a2 and a11-deficient hMSC further reduced in number and did not mineralize the matrix even on a single cell level. Moreover, our preliminary investigation in hMSC-derived from osteoporosis suffering patients showed a tremendous downregulation of integrin a2. Conclusions: Our results strongly suggested that integrins a2b1 and a11b1 mediate an indis-pensible signaling for hMSC. Once these receptors were ablated from cell surface, hMSC re-duced their spreading, adhesion, migration and survival rates. Our integrin knockdown mod-els can be used for further investigations and understanding of the integrins a2b1 and a11b1 importance and signaling in hMSC and hOB since we observed a strong downregulation of integrin a2 expression in osteoporosis.

This show is going to blow you away!.... Our special guest is the esteemed JAN A. NOLTA Ph.D., Director Professor, UC Davis Stem Cell Program and Institute for Regenerative Cures…. She and other amazing scientists have been working day and night to bring us the first HD Stem Cell Clinical Trial…. This is History in the making for the potential CURE of Huntington's Disease!!... DR. NOLTA joined UC Davis in 2006 after serving for five years as scientific director of the cell processing and gene therapy Good Manufacturing Practice (GMP) facility at Washington University School of Medicine in St. Louis…. Her laboratory uses human stem and progenitor populations to examine their recruitment to areas of tissue damage in immune deficient mice…. Her research is focused on developing improved stem cell therapies for treating neurodegenerative diseases including Huntington's and Parkinson's diseases and ALS, Liver disease, lysosomal storage diseases, and peripheral vascular disease…. Her group focuses on “bench to the bedside” research, and she has been involved in numerous clinical trials of gene and cell therapy….. The Institute for Regenerative Cures is located in a 109,000 sq ft facility in Sacramento. Renovation of the old California State Fair building was made possible through a grant from the California Institute for Regenerative Medicine (CIRM), for $20 million of the $63 million dollars total to complete all three phases of the renovation…. DR. NOLTA is published in over 100 peer-reviewed manuscripts and numerous books…. Her most recent book “Genetic Engineering of Mesenchymal Stem Cells” is available on her website….Visit the JAN NOLTA LAB 2010 online for more information about what she is doing for Huntington's disease research….COPY THIS LINK TO YOUR BROWSER…. http://jannolta.com/

Osteogenic differentiation of hMSC into osteoblasts is a prerequisite for subsequent bone formation. Numerous studies have explored osteogenic differentiation under standard tissue culture conditions, which usually employ 21% of oxygen. However, bone precursor cells such as hMSC reside in stem cell niches of low oxygen atmospheres. Furthermore, they are subjected to low oxygen concentrations when cultured on three dimensional scaffolds in vitro for bone tissue engineering purposes, and even more so after transplantation when vascularisation has yet to be established. Similarly, hMSC are exposed to low oxygen in the fracture microenvironment following bony injury. Recent studies revealed that hypoxic preconditioning improves cellular engraftment and survival in low oxygen atmospheres. In the present study we therefore investigated the osteogenic differentiation potential of hMSC under 2% O2 (hypoxia) in comparison to a standard tissue culture oxygen atmosphere of 21% (normoxia). The success of differentiation was validated through Alizarin red staining and RT-PCR analysis of osteoblast markers ALP and OPN. We assessed osteogenic differentiation of hMSC following hypoxic preconditioning to address whether this pretreatment is beneficial for subsequent differentiation under low oxygen tension. To validate our findings we carefully characterised the extent of hypoxia exerted on cells with respect to cell survival (WST assay) and proliferation (growth curve). Furthermore we also tried to elucidate the role of HIF-1 alpha with respect to osteogenic differentiation under hypoxia via silencing RNA and DFO, a pharmacological agent. Finally we tested whether an immortalized hMSC-line (SCP-1) would serve as a model system for hMSC. We found that hMSC proliferate better if cultured under 2% of oxygen. We confirmed that osteogenic differentiation of hMSC is indeed inhibited under hypoxia. We showed for the first time that hypoxic preconditioning of hMSC prior to osteogenic induction restores osteogenic differentiation of hMSC under hypoxia. HIF-1 alpha seemed not to play a significant role in osteogenic differentiation under hypoxia, as transiently knocking down of HIF-1 alpha in preconditioned samples did not show any differences in their osteogenic differentiation. Moreover stabilising Hif-1 alpha in hypoxic samples did not yield any osteogenic differentiation either substantiating the notion that HIF-1 alpha does not have a direct role in the osteogenic differentiation of hMSC under hypoxia. Together our data suggest that hypoxia favours stemness over differentiation by upregulating embryonic stem cell markers like OCT-4 and NANOG. Hypoxic preconditioning may help to restore the otherwise reduced osteogenic potential of hMSC, either within a hypoxic fracture environment or at the site of implantation of tissue engineered bone constructs. We therefore believe that hypoxic preconditioning is a helpful tool for successful regenerative cell-based therapies in bone tissue engineering. SCP-1 cells might be used as a model system for hMSC as they are easy to handle, can be cultured to a desired cell number within a very short period of time, are relatively inexpensive and above all do not go into senescence as seen with hMSC after approximately 20 passages. Apart from their distinct advantages SCP-1 cells still maintain the specific CD markers characteristic for hMSC and are able to differentiate into adipogenic, osteogenic and chondrogenic lineages. However for in vivo experiments in animals a constant monitoring of neoplastic transformation is mandatory

Introduction: Osteoarthritis (OA) and rheumatoid arthritis (RA) are characterised by joint inflammation and cartilage degradation. Although mesenchymal stem cell (MSC)-like progenitors are resident in the superficial zone of articular cartilage, damaged tissue does not possess the capacity for regeneration. The high levels of pro-inflammatory cytokines present in OA/RA joints may impede the chondrogenic differentiation of these progenitors. Interleukin (IL)-1 beta activates the transcription factor nuclear factor-KB (NF-KB), which in turn activates proteins involved in matrix degradation, inflammation and apoptosis. Curcumin is a phytochemical capable of inhibiting IL-1 beta-induced activation of NF-KB and expression of apoptotic and pro-inflammatory genes in chondrocytes. Therefore, the aim of the present study was to evaluate the influence of curcumin on IL-1 beta-induced NF-KB signalling pathway in MSCs during chondrogenic differentiation. Methods: MSCs were either cultured in a ratio of 1:1 with primary chondrocytes in high-density culture or cultured alone in monolayer with/without curcumin and/or IL-1 beta. Results: We demonstrate that although curcumin alone does not have chondrogenic effects on MSCs, it inhibits IL-1 beta-induced activation of NF-KB, activation of caspase-3 and cyclooxygenase-2 in MSCs time and concentration dependently, as it does in chondrocytes. In IL-1 beta stimulated co-cultures, four-hour pre-treatment with curcumin significantly enhanced the production of collagen type II, cartilage specific proteoglycans (CSPGs), beta 1-integrin, as well as activating MAPKinase signaling and suppressing caspase-3 and cyclooxygenase-2. Conclusions: Curcumin treatment may help establish a microenvironment in which the effects of pro-inflammatory cytokines are antagonized, thus facilitating chondrogenesis of MSC-like progenitor cells in vivo. This strategy may support the regeneration of articular cartilage.

The main aim of this thesis was to find out which donor cells would be most suitable for production of cloned rabbits with a targeted modification of their genome, and their corresponding patterns of reprogramming hetero- and euchromatic histone modifications (H3K4m2/3 and H3K27m3). For these purposes, we carried out NT with rabbit mesenchymal stem cells (MSCs) and adult fibroblasts (RAFs). As totally 13 cell lines of MSCs have been tested, they didn’t show stably higher development potential than RAFs, even though the blastocyst rate of embryos cloned from MSC A/B reached to 76%. Finally two cloned rabbits were produced from meschnymal stem cells. H3K27m3 was undetectable in all stages of nuclear transfer embryos except for one cell stage and blastocysts. It seems that H3K27m3 is faithfully reprogrammed in transferred nuclei of all donor cell types, with minor differences in zygotes and blastocysts. Strong signals for H3K4m2/3 were detected at the one to two-cell stages of in vivo embryos with a slight decrease at the 4-cell stage, followed by a more drastic decrease at the 8-cell stage, where the signal minimum was reached. In 16-cell embryos signals slightly increased and then reached in morulae and blastocysts the levels observed in one-two cell embryos. In all types of nuclear transfer embryos fluorescence intensity ratios differed from that of in vivo embryos. The minimum was not reached at the 8-cell stage but at the 4-cell stage. Reprogramming of H3K4m2/3 modification occurred quite differently with either type of cells irrespective of the cell origin or type and no close similarities in the patterns of this reprogramming was observed between in vivo and nuclear transfer embryos. Embryos cloned from MSC A/B differed from all others in the way that H3K4m2/3 was generally lower and remained in the range of the donor cells. This suggests that reprogramming of H3K4m2/3 modification is more aberrant with MSC A/B cells than with any other cell type used in this study. However, with MSC A/B cells, a significantly higher or similar proportion of cloned embryos developed to blastocysts indicating that reprogramming of H3K4m2/3 modification does not correlate with developmental potential of donor cells. In conclusion, our study provides evidence that histone modifications for heterochromatin are faithfully reprogrammed during NT of rabbit somatic cells, while patterns of epigenetic reprogramming of euchromatic histone modifications differ between individual cell lines irrespective of their origin or type and are not correlated with their developmental potential. Although MSCs were not superior to RAFs in respect to the criteria tested in our study they may be suitable nuclear donors for generating transgenic cloned rabbits due to their high developmental plasticity.

We have previously shown that soluble factors derived from mesenchymal stem cells (MSCs) induce oligodendrogenic fate and differentiation in adult rat neural progenitors (NPCs) in vitro. Here, we investigated if this pro-oligodendrogenic effect is maintained after cells have been transplanted onto rat hippocampal slice cultures, a CNS-organotypic environment. We first tested whether NPCs, that were pre-differentiated in vitro by MSC-derived conditioned medium, would generate oligodendrocytes after transplantation. This approach resulted in the loss of grafted NPCs, suggesting that oligodendroglial pre-differentiated cells could not integrate in the tissue and therefore did not survive grafting. However, when NPCs together with MSCs were transplanted in situ into hippocampal slice cultures, the grafted NPCs survived and the majority of them differentiated into oligodendrocytes. In contrast to the prevalent oligodendroglial differentiation in case of the NPC/MSC co-transplantation, naive NPCs transplanted in the absence of MSCs differentiated predominantly into astrocytes. In summary, the pro-oligodendrogenic activity of MSCs was maintained only after co-transplantation into hippocampal slice cultures. Therefore, in the otherwise astrogenic milieu, MSCs established an oligodendrogenic niche for transplanted NPCs, and thus, co-transplantation of MSCs with NPCs might provide an attractive approach to re-myelinate the various regions of the diseased CNS. Copyright (C) 2009 S. Karger AG, Basel